One Day Advisor

Asia is home to some of the world's largest and most influential financial institutions. As of 2026, Chinese banks continue to dominate the rankings of Asia's most valuable banks, highlighting China's growing economic influence and the immense scale of its financial system. According to recent market capitalization data, the four most valuable banks in Asia are all Chinese institutions. Together, China's leading banks account for approximately $1.6 trillion in market value, significantly outpacing competitors from Japan, Singapore, and India. In this article, we examine the rankings, key trends, and what these banking giants reveal about the future of Asia's financial sector. Asia's Top 10 Most Valuable Banks (2026) China Construction Bank – $409 billion Agricultural Bank of China – $345 billion Industrial and Commercial Bank of China (ICBC) – $318 billion Bank of China – $295 billion Mitsubishi UFJ Financial Group – $222 billion China Merch...

Last updated: August 2026 The world's largest banks are not distributed evenly across the global financial system. China dominates the top of the global rankings by total assets, the United States remains home to the world's most powerful banking franchise by market reach and market capitalization, Europe contains several universal banking giants, while Brazil, Japan, India, Singapore, the Gulf states and Australia anchor their respective regional banking systems. This guide ranks the largest banks in the world by region , using total assets as the primary measure of banking scale. It also explains why the largest bank by assets is not necessarily the most valuable bank by market capitalization, the most profitable bank, or the bank with the largest customer base. The latest comprehensive S&P Global Market Intelligence ranking, published in April 2026, is primarily based on bank assets as of December 31, 2025 . The rankings therefore represent the latest comparable f...

Originally published June 2025 · Updated August 24, 2026 with final full-year 2025 results reported in company 10-Ks, 20-Fs, and Q4 earnings releases Quick Answer Merck's Keytruda stayed the world's best-selling drug in 2025 at $31.68 billion , but the bigger story was tirzepatide: Eli Lilly's Mounjaro ($22.97B) and Zepbound ($13.54B) combined for $36.5 billion , overtaking Novo Nordisk's Ozempic-and-Wegovy semaglutide franchise (roughly $31.8B) for the first time. Counting both BMS's and Pfizer's booked shares, Eliquis jumped to #3 at $22.4 billion. The top 10 drugs together generated $188.1 billion in 2025, up 21.5% from 2024. Wegovy narrowly fell out of the top 10, edged out by the Jardiance family. On this page The Final 2025 Ranking Highlights and Market Trends Drug-by-Drug Profiles The GLP-1 Story: Tirzepatide Overtakes Semaglutide Just Missed the Cut (#11–15) Patent Cliffs to Watch 2026 So Far: An Early Look Methodology and...

Global Healthcare Master List | Updated August 2026 Which are the largest healthcare companies in the world in 2026? This master database tracks major healthcare companies with approximately US$1 billion or more in annual or trailing-twelve-month revenue , grouped by country and healthcare sector. Unlike traditional pharmaceutical rankings, this database covers the entire healthcare ecosystem — pharmaceuticals, biotechnology, hospitals, healthcare services, medical devices, diagnostics, contract research, CDMOs, pharmaceutical distribution and healthcare insurance. US$1B+ Revenue inclusion threshold 8 Healthcare sectors 200+ Target companies 30+ Countries represented What counts as a healthcare company? A company is included when healthcare is a material part of its business and its latest reported annual or TTM revenue is approximately US$1 billion or more. Companies are classified by their principal business model rather than being treat...